文献速递胸部肿瘤

HLA I类抗原加工提呈缺陷介导肺癌免疫检查点抑制剂获得性耐药

Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer.
PubMed 文献 · Cancer Discov · 2017-10-12

研究利用14例ICI耐药肺癌样本探究HLA I类抗原加工提呈机器(APM)组分或干扰素信号基因改变在PD-1/PD-L1抗体获得性耐药中的作用。未检测到复发性突变或拷贝数改变;1例发现B2M获得性纯合缺失导致肿瘤及匹配PDX细胞表面HLA I类表达缺失,另2例ICI耐药肿瘤来源PDX亦见B2M下调。免疫健全肺癌小鼠模型CRISPR敲除B2m可体内导致PD-1阻断耐药,证明HLA I类APM破坏可介导肺癌ICI逃逸。

要点

  • 14例ICI耐药肺癌中未检测到APM或干扰素信号基因的复发性突变或拷贝数改变。
  • 1例ICI耐药肺癌及其匹配PDX存在B2M获得性纯合缺失,导致细胞表面HLA I类表达缺失。
  • 免疫健全肺癌小鼠模型CRISPR敲除B2m可体内导致PD-1阻断耐药。

核心结论

  • HLA I类抗原加工提呈机器破坏可介导肺癌对免疫检查点抑制剂的获得性耐药。

研究设计与样本

  • 研究利用14例ICI耐药肺癌样本,探究HLA I类APM组分或干扰素信号基因改变在PD-1或PD-L1抗体获得性耐药中的作用。

主要发现

  • 14例ICI耐药肺癌样本中未检测到复发性突变或拷贝数改变。
  • 1例ICI耐药肺癌发现B2M获得性纯合缺失,导致肿瘤及匹配PDX细胞表面HLA I类表达缺失。
  • 另2例ICI耐药肿瘤来源PDX中亦发现B2M下调。
  • 免疫健全肺癌小鼠模型CRISPR敲除B2m可体内导致PD-1阻断耐药。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs. These results indicate that HLA Class I APM disruption can mediate escape from ICIs in lung cancer.Significance: As programmed death 1 axis inhibitors are becoming more established in standard treatment algorithms for diverse malignancies, acquired resistance to these therapies is increasingly being encountered. Here, we found that defective antigen processing and presentation can serve as a mechanism of such resistance in lung cancer. Cancer Discov; 7(12); 1420-35. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1355.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Gettinger S, Choi J, Hastings K, et al. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Cancer Discov. 2017. PMID: 29025772. doi:10.1158/2159-8290.CD-17-0593

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。